Firm says stent won back share of market
242397
Boston Scientific Corp. said yesterday it has won back the market share that its flagship cardiac stent system held before three safety recalls reduced doctors' orders of the product.
253054
A jury in Texas has ruled that Boston Scientificâs drug-coated stents infringe a 1997 patent issued to a radiologist in Princeton, N.J., and has awarded the inventor $431 million in damages, Boston Scientific said Tuesday. The suit by the patent holder, Dr. Bruce N. Saffran, did not seek to halt sales of the stents.
455531
A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents.
61937
NEW YORK - Johnson &amp; Johnson and Boston Scientific Corp. reported new safety data yesterday for drug-coated stents that may help revive sales depressed by prior reports linking the devices to a higher risk of heart attacks.
256105
The private equity business hit bumps. A deal was struck for a possible Dow Jones sale, and the Supreme Court struck down a longstanding rule on product pricing.
471001
Boston Scientific Corp. said Monday that it received Food and Drug Administration clearance to market a device designed to lower the risk of heart attacks during angioplasty and stenting procedures.
637892
Boston Scientific receives a warning letter from the FDA on a discontinued stent trial.
222527
Johnson & Johnson on Thursday said it has voluntarily withdrawn 300 of its Cypher stents from the U.S. market after determining that the coating on six of the devices did not meet specifications.
200231
A Texas jury has ruled that Boston Scientificâs drug-coated stents infringe a 1997 patent issued to a radiologist and has awarded the inventor $431 million in damages, Boston Scientific said.
93936
The concerns that have been raised about the safety of drug-eluting stents at a major cardiology conference shouldn't mean it's time to go back to older treatments, the chief medical and scientific officer of Natick medical technology company Boston Scientific Corp. said yesterday.
588272
Boston Scientific Corp. shipped millions of dollars worth of coronary stents in fall 1998 even after company officials learned that the medical devices had high failure rates and may not have met specifications approved by the Food and Drug Administration.
8921
SuperGen Inc. SUPG.O on Monday said  it has withdrawn an application to market its pancreatic cancer  drug in the United States, casting a cloud on the drug's future  in the world's biggest market and sending the company's shares  down as much as 16 percent.
377715
The Medicare program is rethinking its blanket coverage for all uses of drug-coated heart stents, a potential blow to Boston Scientific Corp. , Johnson &amp; Johnson, and others in the $6 billion-a-year industry.
741865
Drug-coated heart stents on the U.S. market are associated with a small but significant risk of blood clots months after they are implanted, U.S. Food and Drug Administration staff said in documents released on Tuesday.
751075
uidant received approval yesterday from the Food and Drug Administration to sell stents that are inserted into the main neck artery to reduce the risk of strokes, making the company the
324653
Abbottâs stock price has fallen more than 7 percent since early October amid worries about whether the F.D.A. will speedily approve the companyâs Xience heart stent.
115320
Shares of Boston Scientific Corp. (BSX.N: Quote, Profile, Research) slid more than 3 percent in premarket trading on Wednesday after reporting that sales of its Taxus stent slowed